pharmaphorum March 12, 2025
Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its tally of weight-loss candidates in clinical development to five.
The massive deal – which includes another $250 million over the next two years and could be worth up to $5.3 billion to Denmark-based Zealand if clinical and sales milestones are achieved – focuses on long-acting amylin analogue petrelintide, which recently generated positive results in a 16-week phase 1b trial, including a near 9% weight loss over 16 weeks at the highest dose.
Roche’s move for the asset comes shortly after Zealand started the phase 2b ZUPREME-1 trial of petrelintide in people overweight or obese, and ahead of the ZUPREME-2 study...
Today's Sponsors
Today's Sponsor